Brief: Altamira Therapeutics Says Progressing With Plans To Focus On RNA Business
30/08/2022 14:29
Aug 30 (Reuters) - Altamira Therapeutics Ltd CYTO.O :
* ALTAMIRA THERAPEUTICS PROVIDES BUSINESS UPDATE
* ALTAMIRA THERAPEUTICS LTD - COMPANY PROGRESSING WITH PLANS
TO
FOCUS ON ITS RNA BUSINESS
* ALTAMIRA THERAPEUTICS LTD - ADVANCING DISCUSSIONS FOR
DIVESTITURE OR SPIN-OFF OF LEGACY ASSETS, INCLUDING BENTRIOTM
AND AM-125 NASAL SPRAYS
Source text for Eikon: ID:nGNX4Rs5xl
Further company coverage: CYTO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Altamira Therapeutics
See all newsBrief: Altamira Therapeutics Reports Full Year 2024 Results
Brief: Altamira Therapeutics Announces Transition From Nasdaq To OTC Markets
Brief: Altamira Therapeutics Provides Update On Nasdaq Listing
Brief: Altamira Therapeutics Provides Business Update And First Half 2024 Financial Results
Brief: Altamira Therapeutics Announces Pricing Of Up To $12.0 Mln Public Offering